eligibility_summary
Eligibility: women 18–75 with HR+/HER2–, PD‑L1+ adv/met BC, ECOG 0–1, progressed after ≥2 endocrine lines (incl ≥1 CDK4/6‑based) and ≥1 chemo for MBC, RECIST‑measurable, LE≥3 mo, WOCBP contraception. Exclude leptomeningeal or active/untreated CNS mets, prior anti‑TROP‑2, PD‑(L)1 or topo‑ADC, uncontrolled effusions, recent anticancer therapy, autoimmunity/immunodeficiency, active HBV/HCV/cirrhosis/infection, immunosuppression, ILD/pneumonitis, uncontrolled CV, live vaccine <4w, other cancer <5y.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study in endocrine therapy–refractory, HR-positive/HER2-negative, PD-L1–positive advanced breast cancer tests two agents: 1) SHR-A1921: an anti–TROP-2 antibody–drug conjugate (ADC). Mechanism: binds TROP-2 on tumor cells, is internalized, and releases a cytotoxic payload to kill TROP-2–expressing cancer cells. 2) Adebrelimab: a PD-L1–blocking monoclonal antibody (immune checkpoint inhibitor). Mechanism: blocks PD-L1 to prevent PD-1/PD-L1 signaling, restoring cytotoxic T-cell activity against tumors. Targets/pathways: TROP-2 on breast cancer cells (for ADC-directed cytotoxicity) and the PD-1/PD-L1 immune checkpoint on tumor and immune cells (to enhance T-cell–mediated antitumor responses). Both administered IV.